学习经历：

2005-2009    华中科技大学同济药学院   中药学 学士

2009-2014    中国科学院广州生物医药与健康研究院   药物化学 博士

工作经历

2014-2015    美国梅奥医院 (Mayo Clinic)    博士后

2015-2019    明尼苏达大学药物化学系/Masonic癌症中心 博士后

2019-2023    明尼苏达大学Masonic癌症中心   Researcher 6

2021-2023    明尼苏达大学药物化学系   研究助理教授

2023-2025    德克萨斯大学El Paso分校药物科学系    助理教授

2026-现在    中国科学院广州生物医药与健康研究院   研究员

截止目前，共在本研究领域发表期刊论文30余篇，授权发明专利4项。

近五年发表论文（# co-first author; * corresponding author）

[1] Ding K*, Li Y, Zhou Y, Huang W. Chemical Adaptation in Drug Discovery: The Medicinal Chemistry Journey of Olverembatinib and Limertinib in Overcoming Kinase Drug Resistance.Acc. Chem. Res. 2025, 58(20), 3195-3209.

[2] Zhang H, Li Y*. Temozolomide-Derived Therapeutic Strategies to Overcome Resistance in Glioblastoma. J. Med. Chem. 2025, 68(18), 18810-18828.

[3] Guo W#, Gao Y#, Du D, Sanchez JE, Li Y, Qiu W*, Li L*. Elucidating the interactions between Kinesin-5/BimC and the microtubule: insights from TIRF microscopy and molecular dynamics simulations. Brief. Bioinform, 2025, 26(2), bbaf144.

[4] Zhang H#, Tu Y#, Tao Z#, Gao L, Huang S, Gao M, Mao J, Zhou Y, Li Y, Li J*, Zhou Y*, Xu T*. Design, synthesis and biological evaluation of 2,4-diaminopyrimidine derivatives as potent cyclin-dependent kinase 7 inhibitors. ACS Med Chem Lett 2024, 15(8), 1213-1220.

[5] Li Y*, Tang MK*, Carmella SG, Peters CP, Cohen JD, Hegeman AD, Hecht SS*. Hydroponic growth of [13C]-labeled tobacco for DNA damage studies in cigarette smokers. J Agric Food Chem 2024, 72 (30), 16594-16602. (Cover Paper)

[6] Li Y*. DNA adducts in cancer chemotherapy. J. Med. Chem. 2024, 67 (7), 5113-5143.

[7] Fabitha K, Kallingal A, Maciejewska N, Arya CG, Chandrakanth M, Thomas NM, Li Y, Gondru R, Munikumar M, Banothu J*. Revealing novel fused pyran derivatives: Their discovery as potent anticancer agents and mechanistic insights. New J Chem 2024, 48, 8038-8054. (Cover Paper)

[8] Zhou C#, Fan Z#, Gu Y#, Ge Z#, Tao Z, Cui R, Li Y, Zhou G, Huo R, Gao M, Wang D, He W, Zheng M*, Zhang S*, Xu T*. Design, synthesis, and biological evaluation of potent and selective PROTAC degraders of oncogenic KRASG12D. J. Med. Chem. 2024, 67 (2), 1147-1167.

[9] Li Y*, Dator R, Maertens L, Balbo S, Hecht SS. Mass spectrometry-based metabolic profiling of urinary metabolites of N′-nitrosonornicotine (NNN) in the rat. Chem. Res. Toxicol. 2023, 36 (5), 769-781. (Cover Paper)

[10] Guidolin V#, Li Y#, Jacobs F, MacMillan ML, Villalta PW, Hecht SS, Balbo S*. Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy. Mol. Ther. Oncolytics. 2023, 28, 197-210.

[11] Zhou Z#, Zhou G#, Zhou C#, Fan Z, Cui R, Li Y, Li R, Gu Y, Li H, Ge Z, Cai X, Jiang B, Wang D, Zhang S*, Xu T*, Zheng M*. Discovery of a potent and selective SOS1 PROTAC ZZ151: Exploration of degradation activity cliffs and antitumor efficacy in KRAS-mutated cancers. J. Med. Chem. 2023, 66 (6), 4197-4214.

[12] Liu M#, Zhou G#, Su W#, Gu Y, Gao M, Wang K, Huo R, Li Y, Zhou Z, Chen K, Zheng M, Zhang S*, Xu T*. Design, synthesis and bioevaluation of pyrido[2,3-d]pyrimidin-7-ones as potent SOS1 inhibitors. ACS Med. Chem. Lett. 2023, 14 (2), 183-190.

[13] Zhang Y#, Guo R#, Chen Y, Li T, Du W, Xiang R, Guang J, Li Y, Huang Y, Yu Z, Cai Y, Zhang P*, Ling G*. Ionizable drug delivery systems for efficient and selective gene therapies. Mil. Med. Res. 2023, 10 (1), 9.

[14] Li Y*, Hecht SS. Mass spectrometric quantitation of N′-Nitrosonornicotine-1N-oxide in the urine of cigarette smokers and smokeless tobacco users. Chem. Res. Toxicol. 2022, 35, 1579-1588. (Cover Paper)

[15] Li Y*, Hecht SS. Metabolic activation and DNA interactions of carcinogenic N-nitrosamines to which humans are commonly exposed. Int. J. Mol. Sci. 2022, 23 (9), 4559.

[16] Li Y*, Hecht SS. Metabolism and DNA adduct formation of tobacco-specific N-nitrosamines. Int. J. Mol. Sci. 2022, 23 (9), 5109.

[17] Li Y*, Hecht SS*. Carcinogenic components of tobacco and tobacco smoke: A 2022 update. Food Chem. Toxicol. 2022, 165, 113179.

[18] Arya CG, Gondru R, Li Y*, Banothu J*. Coumarin–benzimidazole hybrids: a review of developments in medicinal chemistry. Eur. J. Med. Chem. 2022, 227, 113921.

[19] Fabitha K, Chandrakanth M, Pramod RN, Arya CG, Li Y, Banothu J*. Recent developments in the synthesis of indole-pyrazole hybrids. ChemistrySelect 2022, 7, e202201064.

[20] Zhou C#, Fan Z#, Zhou Z#, Li Y, Cui R, Liu C, Zhou G, Diao X, Jiang H, Zheng M*, Zhang S*, Xu T*. Discovery of the first-in-class agonist-based SOS1 PROTACs effective in human cancer cells harboring various KRAS mutations. J. Med. Chem. 2022, 65, 3923-3942.

[21] Zhang H#, Xie R#, AI-furas H, Li Y, Wu Q, Li J*, Xu F*, Xu T*. Design, synthesis and biological evaluation of novel EGFR PROTACs targeting Del19/T790M/C797S mutation. ACS Med. Chem. Lett. 2022, 13, 278-283.

[22] Li Y, Carlson ES, Zarth AT, Upadhyaya P, Hecht SS*. Investigation of 2′-deoxyguanosine-derived adducts specifically formed in rat liver and lung DNA by N′-nitrosonornicotine (NNN) metabolism. Chem. Res. Toxicol. 2021, 34 (4), 1004-1015.

[23] Li Y, Hecht SS*. Identification of an N′-nitrosonornicotine-specific deoxyguanosine adduct in rat liver and lung DNA. Chem. Res. Toxicol. 2021, 34 (4), 992-1003.

已授权专利

[1] David S, Li Y, Brush M, Trautman K, Gustafson C, Maurer D, Pathakumari B. Therapeutic compounds and methods of use thereof. US12060350B2, granted on 08/2024.

[2] Ding K, Lu X, Zhang T, Tang J, Lu M, Li Y, Zhang Z, Liang Z, Qian Z. Preparation method and use of N-4-trifluoromethylphenylsalicylamide derivatives. CN104873522(B), granted on 06/2019.

[3] Ding K, Li Y, Shen M, Long H, Zhang Z, Leng F, Lu X. Heterocylic benzamide compounds, pharmaceutical compositions as well as application thereof. CN103539784(B), granted on 08/2016.

[4] Ding K, Feng Y, Lu X, Li W, Li Y, Shen M. Synthesis method of ponatinib. CN103570724(B), granted on 12/2015.